• Louise K François Watkins, Alison Winstead, Grace D Appiah, Cindy R Friedman, Felicita Medalla, Michael J Hughes, Meseret G Birhane, Zachary D Schneider, Perrine Marcenac, Samir S Hanna, Gauri Godbole, Kelly A Walblay, Ashley E Wiggington, Molly Leeper, Elizabeth H Meservey, Kaitlin A Tagg, Jessica C Chen, Abdinasir Abubakar, Faris Lami, Asaad M Asaad, Vickneswaran Sabaratnam, Aamer Ikram, Kristina M Angelo, Allison Walker, and Eric Mintz.
• MMWR Morb. Mortal. Wkly. Rep. 2020 May 22; 69 (20): 618-622.

AbstractCeftriaxone-resistant Salmonella enterica serotype Typhi (Typhi), the bacterium that causes typhoid fever, is a growing public health threat. Extensively drug-resistant (XDR) Typhi is resistant to ceftriaxone and other antibiotics used for treatment, including ampicillin, chloramphenicol, ciprofloxacin, and trimethoprim-sulfamethoxazole (1). In March 2018, CDC began enhanced surveillance for ceftriaxone-resistant Typhi in response to an ongoing outbreak of XDR typhoid fever in Pakistan. CDC had previously reported the first five cases of XDR Typhi in the United States among patients who had spent time in Pakistan (2). These illnesses represented the first cases of ceftriaxone-resistant Typhi documented in the United States (3). This report provides an update on U.S. cases of XDR typhoid fever linked to Pakistan and describes a new, unrelated cluster of ceftriaxone-resistant Typhi infections linked to Iraq. Travelers to areas with endemic Typhi should receive typhoid vaccination before traveling and adhere to safe food and water precautions (4). Treatment of patients with typhoid fever should be guided by antimicrobial susceptibility testing whenever possible (5), and clinicians should consider travel history when selecting empiric therapy.

30 keywords...

hide…